biological activity | C75 trans (trans-C75, (±)-C75) is a new and effective synthetic inhibitor of fatty acid synthase (FAS/FASN). The IC50 values in plant test and sphere growth determination are 35 μM and 50 μM respectively. C75 can be used as a tool to study the synthesis of fatty acids in metabolic disorders and cancer. |
target | TargetValue FASN (clonogenic say) 35 μM FASN (spheroid growth say) 50 μM |
Target | Value |
FASN
(clonogenic assay)
| 35 μM |
FASN
(spheroid growth assay)
| 50 μM |
in vitro study | trans-C75 (()-C75) inhibits PC3 cell growth with an IC 50 of 35 μ m at 24 h. trans-C75 (()-C75)(10-50 μ m) also reduces the growth of LNCaP spheroids in a concentration-dependent manner with an IC 50 of 50 μ m. trans-C75 (()-C75) inhibits FAS activity and has a cytotoxic effect on tumor cell lines, without affecting food consumption. trans-C75 (()-C75) inhibits CPT1 and its administration produces anorexia, suggesting that central inhibition of CPT1 is essential for the anorectic effect of C75. The differential activity of C75 enantiomers may lead to the development of potential new specific drugs for cancer and obesity. |
in vivo studies | C75 blocks fasting-induced c-Fos expression in the arcuate nucleus (Arc), lateral hypothalamic area (LHA), and paraventricular nucleus (PVN) 10-24 h after I. p. injection. Intraperitoneal administration of C75 at 30 mg/kg body weight inhibits food intake of mice by ≥ 95% within 2 h after I. p. injection. C75-treated DIO mice has a 50% greater weight loss, and a 32.9% increased production of energy because of fatty acid oxidation. C75 treatment of rodent adipocytes and hepatocytes and human breast cancer cells increases fatty acid oxidation and ATP levels by increasing CPT-1 activity, even in the presence of elevated concentrations of malonyl-CoA. |